We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VB-111

News List

VBL Announces Patient Dosing of Recurrent Glioblastoma Multiforme Trial americanpharmaceuticalreview
March 04, 2021
VBL Therapeutics announced patient dosing has been initiated in a Phase 2 clinical trial investigating ofranergene obadenovec (VB-111) for the treatment of recurrent glioblastoma multiforme (rGBM).
Data Safety Monitoring Committee Green Lights Ovarian Cancer Study americanpharmaceuticalreview
February 24, 2021
VBL Therapeutics announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer.
VBL Enrolls First Patients in VB-111 Trial for Metastatic Colorectal Cancer americanpharmaceuticalreview
September 18, 2020
VBL Therapeutics announced the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer.